CytoDyn Inc. (CYDY) Finding Success in Trials of PRO 140 for Treatment of HIV/AIDS; Plans to Expand Clinical Investigations to Cancer

October 25, 2018 11:07:40
  • Lead product candidate, PRO 140, is a viral-entry inhibitor that works by blocking the entry of HIV/AIDS to healthy cells by masking CCR5 receptor
  • Completion of Biological License Application (BLA) for potential approval in combination HIV therapy expected in Q1 2019
  • CytoDyn received approval to increase dosing of PRO 140 in its phase 3 adaptive clinical trial for enrolled HIV/AIDS patients
  • Market potential for PRO 140 as an anti-viral agent in combination with HAART is $1.2 billion; as a monotherapy maintenance/single-drug therapy, the market is estimated at $3.8 billion
  • Acquisition of privately held ProstaGene expected to complete in November, giving CytoDyn access to CCR5 technologies related to cancer
  • PRO 140 set for Investigational New Drug (IND) application in first cancer indication

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) is focused on providing real hope and help to the millions of people infected with the human immunodeficiency virus (HIV) and those suffering from several devastating forms of cancer. The company’s lead product candidate, PRO 140 (leronlimab), is in advanced stages of clinical development as a therapy for HIV/AIDS, and plans to expand investigations with PRO 140 into cancer are underway. Nader Pourhassan, Ph.D., president and CEO of CytoDyn, updated shareholders during a recent conference call that was highlighted in a corporate summary from leading independent small cap media portal (

The summary includes highlights from the ongoing clinical development of CytoDyn’s PRO 140 viral-entry inhibitor, which has demonstrated a 93 percent suppression rate in 525mg trials after a six-week induction period of enrolled HIV/AIDS patients. The data suggests that the…

Read More>>

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.